TLDR:
- Vilya, a biotechnology company based in Seattle, expanded its Series A financing to $71M.
- The funding round was led by ARCH Venture Partners and included participation from NVentures, Menlo Ventures, Madrona, Lifeforce Capital, and Altitude Life Science Ventures.
In a recent development, Vilya, a biotechnology company based in Seattle, has increased its Series A funding to $71M. The round was spearheaded by ARCH Venture Partners, with a consortium of investors including NVentures, Menlo Ventures, Madrona, Lifeforce Capital, and Altitude Life Science Ventures also participating. This injection of capital will enable Vilya to further accelerate the progress of its innovative computational drug design and development platform, as well as advance its pipeline of novel macrocycles tailored to target disease biology with precision.
Under the leadership of CEO David Baker, Ph.D., and Cyrus Harmon, Ph.D., Vilya is pioneering a new class of medicines leveraging advanced machine learning and generative AI to design molecular structures that bridge the gap between small molecules and antibodies. By tapping into uncharted chemical space and focusing on difficult-to-drug therapeutic targets, the company aims to revolutionize the treatment of diseases.
With operations in Seattle and South San Francisco, Vilya’s leadership team includes key figures such as Katerina Leftheris, Ph.D., Chief Scientific Officer, Patrick Salveson, Ph.D., Co-Founder and Chief Technology Officer, and Inca Dieterich, Ph.D., Co-Founder and Vice President of Business Development. The company’s mission is to transform the landscape of biotechnology through innovative drug design and development.
This significant expansion of Vilya’s Series A financing underscores the confidence of leading venture capital firms in the company’s disruptive approach to targeting disease biology. The additional funding will propel Vilya towards achieving its vision of creating precise and effective medicines that address unmet medical needs.
